"There are a lot of treatment options for patients now, " says Memorial Sloan-Kettering Cancer Center's Robert Motzer, who led the study.

FORBES: Magazine Article

Afinitor delayed disease progression in patients with kidney cancer by a modest three months in a 416-patient trial led by Robert Motzer, an oncologist at Memorial Sloan-Kettering Cancer Center.

FORBES: Health

Memorial Sloan-Kettering's Motzer looks at the big picture.

FORBES: Health

In June oncologist Robert Motzer of New York's Memorial Sloan-Kettering Cancer Center reported that SU11248 dramatically shrank tumors in 33% of 63 kidney cancer patients tested (including Judy Norris) and halted tumor growth in another 37%.

FORBES: Health